Last reviewed · How we verify
NCT05942768
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer
trial testing regorafenib plus anti-PD-1 antibodies in Metastatic Colorectal Adenocarcinoma in 103 participants. Completed in 30 September 2021.
30 June 2021
Quick facts
| Lead sponsor | Hunan Cancer Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 103 |
| Start date | 1 July 2019 |
| Primary completion | 30 June 2021 |
| Estimated completion | 30 September 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- regorafenib plus anti-PD-1 antibodies — full drug profile →
Conditions studied
- Metastatic Colorectal Adenocarcinoma — all drugs for Metastatic Colorectal Adenocarcinoma →
Sponsor
Hunan Cancer Hospital
Who can join
Adults 18 to 75, any sex, with Metastatic Colorectal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Managements for refractory proficient mismatch repair (pMMR) or microsatellite stable (MSS) metastatic colorectal cancer (mCRC) were still challenging and controversial. Our study sought to investigate the efficacy and safety of anti-PD-1 antibodies plus regorafenib in refractory pMMR/MSS mCRC between July 2019 and June 2021 at the Hunan Cancer Hospital.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05942768
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metastatic Colorectal Adenocarcinoma
Currently open trials in the same condition.
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT07318805 — A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors · Phase 1 · recruiting
- NCT07130903 — Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Met · Phase 2 · recruiting
- NCT06696768 — Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Be · Phase 1 · recruiting
- NCT06336902 — Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorec · Phase 1 · recruiting
Other Hunan Cancer Hospital trials
Trials by the same sponsor.
- NCT07314216 — Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcin · Phase 2 · not yet recruiting
- NCT07083687 — Lorlatinib in ROS1+ NSCLC With Brain Metastasis · Phase 2 · not yet recruiting
- NCT07098026 — Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer · NA · recruiting
- NCT06840704 — Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer · Phase 3 · recruiting
- NCT06788002 — LDRT and Chemoimmunotherapy in NPC With Liver Metastasis · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05942768 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hunan Cancer Hospital
- Last refreshed: 12 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05942768.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing